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SUMMARY
In children lacking influenza-specific adaptive immunity, upper respiratory tract innate immune responses
may influence viral replication and disease outcome. We use trivalent live attenuated influenza vaccine
(LAIV) as a surrogate challenge model in children aged 24–59 months to identify pre-infection mucosal tran-
scriptomic signatures associated with subsequent viral shedding. Upregulation of interferon signaling path-
ways prior to LAIV is significantly associated with lower strain-specific viral loads (VLs) at days 2 and 7.
Several interferon-stimulated genes are differentially expressed in children with pre-LAIV asymptomatic res-
piratory viral infections and negatively correlated with LAIV VLs. Upregulation of genes enriched in macro-
phages, neutrophils, and eosinophils is associated with lower VLs and found more commonly in children
with asymptomatic viral infections. Variability in pre-infection mucosal interferon gene expression in children
may impact the course of subsequent influenza infections. This variability may be due to frequent respiratory
viral infections, demonstrating the potential importance of mucosal virus-virus interactions in children.
INTRODUCTION
Influenza results in significant pediatric morbidity and mortality
worldwide, with the largest burden in low- and middle-income
countries.1 Historical human challenge studies defined the
main known correlate of protection from influenza in adults
based on serum hemagglutination inhibition (HAI) titers.2 In chil-
dren who are influenza naive and have no pre-existing adaptive
immune responses, innate immunity in the upper respiratory
tract (URT) mucosa may be important in determining the risks
of infection as well as severity of disease.
Unlike in adults, ethical and feasibility constraints of con-
ducting influenza challenge studies in children limit the ability
to use this controlled experimental approach to gain insight
into such aspects of protective immunity. We hypothesized
that live attenuated influenza vaccines (LAIVs) could be used
as a surrogate challengemodel in children, with shedding of vac-
cine strains as the primary endpoint of interest. LAIVs contain
influenza strains that replicate in the cooler URT only, showing in-
duction of interferon-stimulated genes (ISGs) and replication ki-
netics similar to that of wild-type strains.3,4 Millions of children
worldwide R2 years of age have received LAIVs for protection
against seasonal influenza viruses to date, with an excellent
safety profile.
Using LAIV challenge in children with no detectable serum HAI
titers to vaccine strains, we sought to define pre-challenge tran-
scriptome signatures in the nasopharyngeal mucosa that were
associated with the degree of viral shedding several days later;
thus, mimicking what may determine the outcome of URT influ-
enza infections in influenza-naive children. We show that many
Cell Reports Medicine 2, 100465, December 21, 2021 ª 2021 The Author(s). 1
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
ll
OPEN ACCESS
children have upregulated interferon pathways at the time of
vaccination that correlate with limited influenza strain shedding
and that upregulated ISG signatures may, in part, be explained




Influenza vaccine-naive children aged 24–59 months were
given one dose of trivalent LAIV (Nasovac-S, Serum Institute of
India) as part of a previously described open-label, prospective,
observational, phase 4 immunogenicity study in The Gambia
(ClinicalTrials.gov NCT02972957).5Children eligible for the study
were clinically well, with no history of respiratory illness within the
last 14 days. We have previously demonstrated the role of serum
antibody in reducing LAIV shedding in children, with no effect
seen from influenza-specific mucosal immunoglobulin A (IgA)
or T cell responses.5 To evaluate mucosal factors influencing
LAIV strain shedding in influenza-naive children, in the current
study we included children who were seronegative (HAI titer <
1:10) to at least one strain and from whom we had adequate
nasopharyngeal RNA for transcriptome profiling (n = 82). Of
these, 48 were seronegative to pH1N1, 41 were seronegative
to H3N2, and 55 were seronegative to influenza B. The study
design is detailed in Figure 1A.
LAIV viral loads and presence of asymptomatic
respiratory viruses at baseline
Nasopharyngeal viral loads at both day 2 and day 7 were signif-
icantly lower in seropositive than seronegative children for a
given influenza strain (Figures 1B and 1C). However, a wide
range was seen within the seronegative children, with some viral
loads equivalent to those in seropositive children, whereas
others were very high at both day 2 and day 7 (Figure 1C).
Asymptomatic respiratory viral infections at baseline were de-
tected in 41.8% (33/79) of children with valid multiplex RT-PCR
assay results (Figure 1D). Twenty-six had rhinovirus (three of
these with other viral co-infections), five had human parain-
fluenza virus-1 (HPIV-1; two with co-infections), four had sea-
sonal coronavirus (CoV) (two with co-infections), and two had
adenovirus (one with co-infection). Asymptomatic respiratory vi-
ruses were detected in 20/39 children aged 24–35 months,
compared with 9/30 children aged 36–47 months and 4/10
children aged 48–59 months. Of note, the study was conducted
during the dry season in The Gambia, when circulation of respi-
ratory viruses is generally lower than during the wet season.6
Transcriptional profiles associated with LAIV shedding
and presence of asymptomatic respiratory viruses
Gene set enrichment analysis (GSEA) was conducted to identify
mucosal transcriptional profiles from nasopharyngeal swabs
taken prior to LAIV challenge that may influence replication of
LAIV strains. Correlation coefficients were generated between
mucosal gene expression at baseline and viral loads at days 2
and 7 for each strain. Negative normalized enrichment scores
(NESs) from the GSEA indicate pathways enriched for genes
whose expression inversely correlates with viral loads and vice
versa. Five pathways were significantly enriched (adjusted p
value < 0.1) for genes associated with lower viral loads for all
three strains at day 2, and of these five pathways, two were
also significant for all three strains at day 7 (Interferon signaling
and Immunoregulatory interactions between a lymphoid and
non-lymphoid cell; Figure 2A; see Table S1 for NESs and
adjusted p values). Greater expression of genes at baseline en-
riched in the Intraflagellar transport and Fatty acid metabolism
pathways were associated with higher viral loads at both day 2
and day 7.
To see whether the presence of asymptomatic respiratory viral
infection could explain upregulated genes from interferon
signaling pathways in some children, differentially expressed
genes (DEGs) between children with and without viral infections
at baseline were identified (817 upregulated, 114 downregu-
lated; Table S2). Twenty eight significantly upregulated DEGs
(Figure 2B) were also found within the gene set contributing to
the GSEA enrichment signal in interferon signaling pathways
(leading edge genes) shown in Figure 2A. The expression of
these genes at baseline was among those negatively correlated
with LAIV viral loads at days 2 and 7 (CIITA, DDX58, EIF2AK2,
GBP4, GBP7, HERC5, IFI6, IFIH1, IFIT1, IFIT2, IFIT3, IRF7,
ISG15, ISG20, MX1, NUP58, OAS2, OAS3, PML, RSAD2,
SOCS, STAT2, TRIM5, TRIM22, TRIM35, USP18, VCAM1,
XAF1). A protein-protein interaction network constructed using
these overlapping genes is shown in Figure 2C, demonstrating
their role within interferon signaling pathways (a minimum
network containing 27 of these genes produced from Network
Analyst7). Examples of inverse correlations between gene
expression prior to LAIV challenge and day 2 viral load are shown
in Figure 2D (see Table S3 for all correlation coefficients). Chil-
dren with higher baseline gene expression and lower viral loads
were made up mostly, but not exclusively, by those with asymp-
tomatic respiratory viruses.
Impact of asymptomatic respiratory viruses and
upregulated interferon pathways on immunogenicity to
LAIV
In keeping with our previous findings of the importance of viral
shedding for induction of immunity to LAIV,5 significant positive
correlations were observed between viral load and increase in
HAI titer from baseline to day 21 for H3N2 (day 2 viral load:
rho = 0.47, p = 0.002; day 7 viral load: rho = 0.71, p < 0.0001)
and influenza B (day 2 viral load: rho = 0.43, p = 0.001; day 7 viral
load: rho = 0.56, p < 0.0001), but not for pH1N1 (Figure S1). No
associations between viral load and induction of CD4+ T cell
responses was observed (Figure S1). No statistically significant
difference in either antibody or T cell response was seen to any
LAIV strain in children with and without asymptomatic respiratory
viruses at baseline (Figure 2E). No significant correlation was also
seen between enrichment for interferon genes at baseline and in-
duction of antibody or T cell responses to LAIV (Figure S2).
Cell-type-specific gene expression signatures
associated with LAIV shedding and presence of
asymptomatic respiratory viruses
Comparisons of cell-type-specific expression scores showed
that samples from children with asymptomatic respiratory








Figure 1. Study design, nasopharyngeal LAIV viral loads, and presence of asymptomatic respiratory viruses
(A) Study design and sampling. Influenza vaccine naive children (n = 82) given a single dose of the northern hemisphere 2017-18 LAIV (Nasovac-S Serum Institute
of India) were included in the study. NPS, nasopharyngeal swab; HAI, hemagglutinin inhibition titer.
(B) Heatmap showing nasopharyngeal viral shedding at days 2 and 7 following LAIV (log10 50% egg infectious dose equivalent [EID50]/mL) for 2009 pandemic
H1N1 (pH1N1), H3N2, and influenza B viruses in children seronegative (HAI titer < 1:10) and seropositive for each corresponding strain. Detection of
asymptomatic respiratory viruses at baseline are displayed, with key for each virus as per Figure 1D (X indicates samples not available for testing). HPIV-1,
human parainfluenza 1; seasonal CoVs, seasonal coronaviruses (229E, OC43, NL63). X denotes children where no result was available due to lack of sample
availability.
(C) Comparison of day 2 and day 7 nasopharyngeal viral loads in children who are seronegative and seropositive to each influenza strain. Red lines denotemedian
value. The p values are from Mann-Whitney U test.
(D) Prevalence of asymptomatic respiratory virus in 33/79 (41.8%) children in nasopharyngeal swabs taken prior to vaccination.
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viruses were significantly enriched for signatures from a variety
of immune cells (e.g., neutrophils, eosinophils, macrophages),
with concomitant reduction in those gene signatures from cili-
ated epithelial cells, goblet cells, and major histocompatibility
complex (MHC) class II high goblet cells (Figure 3A; Figure S3).
The reduction in the proportion of multiciliated epithelial cell sig-
natures in children with respiratory viruses (p = 5e3) was
confirmed by a deconvolution analysis based on single-cell
data from healthy human airways (Figure S4).8,9
To determine the relationship between enrichment for cell-
type-specific signatures prior to LAIV challenge and subsequent
viral load at days 2 and 7, GSEA was repeated using gene viral
load correlation coefficients as rank and the cell-specific gene
list as the reference set.10 Significant enrichment for neutrophil,
eosinophil, and macrophage signatures pre-challenge was
associated with lower viral load at day 2 for all three strains (Fig-
ure 3B; Table S4). Significant enrichment for ciliated epithelial
cell signatures pre-challenge was associated with higher viral
loads at both day 2 and day 7 for all three strains. Finally, to
explore how enrichment for specific cells may be linked to inter-
feron signaling pathway upregulation, correlations between cell-
specific scores and interferon pathway NES from single-sample
GSEA were conducted. Significant positive correlations were
observed between interferon pathway enrichment and signa-
tures for several cell types (e.g., eosinophils, macrophages,
natural killer [NK] cells), with significant inverse correlations
with ciliated epithelial cells, goblet cells, and MHC class II high
goblet cells (Figure 3C; Figure S5).
DISCUSSION
Using live attenuated influenza strains as a surrogate controlled
influenza challenge model in young children, we demonstrate
that pre-existing upregulated interferon pathways in the URT
mucosa may limit the replication of influenza viruses in seroneg-
ative children. Furthermore, we show that these changes may in
part be due to asymptomatic infection with other respiratory vi-
ruses, highlighting the complex interplay between the large
burden of viruses that children are exposed to. Our findings
have implications not only for understanding the reasons for
the heterogenous outcomes from pediatric influenza infec-
tions11 but also more broadly for investigating the divergent out-
comes from other respiratory viral infections such as severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
children.
The ability of interferon to inhibit influenza virus replication in
humans through the induction of ISGs is well described.12 Our
findings are consistent with recent in vitro data from a co-culture
model showing inhibition of pdm09H1N1 influenza virus replica-
tion by preceding human rhinovirus infection via ISG induction.13
This was suggested as a potential explanation for the epidemio-
logical observations of asynchronous circulation of rhinovirus
and influenza A viruses.14 Interference with influenza infections
by other viral co-infections (CoVs, respiratory syncytial virus
[RSV]) has also been shown in murine and ferret models.15,16
Our data clearly demonstrate that asymptomatic respiratory viral
infections are common in children and can cause perturbation of
the nasal mucosal transcriptome. While a previous study found
blood transcriptional responses in children asymptomatic rhino-
virus infection were no different to healthy controls,17 another
study with limited asymptomatic cases found alterations in nasal
samples.18 While beyond the scope of this study, it is possible
that colonizing bacteria and fungi also impact influenza virus
replication, potentially via trained immunity, and should be
explored in future cohorts.
Although inferred from transcriptional signatures alone, our
data also suggest that the composition of cell types in the naso-
pharyngeal mucosa at the time of LAIV infection can impact viral
replication in the first 2 days. Children with baseline gene signa-
tures enriched in macrophages, neutrophils, and eosinophils
were significantly more likely to have lower viral loads at day 2
for all three influenza strains. Macrophages, in particular, are
known to play a key role in interferon induction and control of
influenza infections.19 We also found that signatures from
Figure 2. Baseline transcriptional profiles associated with LAIV strain shedding at day 2 and day 7 in children seronegative to each influenza
strain prior to vaccination
(A) Selected pathways from gene set enrichment analysis (GSEA) using the Spearman correlation coefficients between normalized gene expression (rlog) at
baseline and strain-specific viral loads (log10 EID50/mL) at day 2 and day 7 as rank, and Reactome pathways set. NES, normalized enrichment score. The size of
circles is proportional to the adjustedlog10 p value from GSEA, while the intensity of the circle color denotes the NES for each pathway/strain-specific viral load
combination (deeper color indicates higher NES). Blue circles denote enrichment of genes in nasopharynx prior to LAIV challenge that negatively correlate with
viral load at day 2 and day 7, and red circles denote enrichment of genes that positively correlate with viral loads. Significant pathways (adjusted p value < 0.1) are
highlighted with a black outline. The number of leading edge (LE) genes is provided for each pathway, i.e., genes contributing to the enrichment signal.
(B) Volcano plot of differentially expressed genes (DEGs) at baseline in children with (n = 33) and without (n = 46) asymptomatic viral infections, defined by a log2
fold-change of ±0.5 and adjusted p value of 0.001. The 28 genes from interferon (IFN) signaling pathways in (A) also found in upregulated DEGs are highlighted.
(C) Protein-protein interaction network of overlapping genes (n = 27, shown in orange) from IFN signaling pathways shown in (A) and upregulated DEGs in children
with asymptomatic respiratory viruses shown in (B). Network was constructed using Network Analyst,7 the InnateDB interaction database, and the minimum
network option. Proteins in orange scale are colored by log2 fold-change of corresponding gene in the DEG analysis. Additional connecting protein nodes not
found as DEGs, but are key within the network are shown in gray. Of these, CREBBP, IRF1, RELA, STAT1, and UBC are found within the IFN signaling pathway LE
genes.
(D) Examples of inverse correlation between baseline IFN gene expression and LAIV strain viral load (day 2, H3N2). Rho represents Spearman correlation co-
efficient. Values from children with asymptomatic respiratory viruses detected at baseline are colored purple.
(E) Antibody response (HAI) and hemagglutinin (HA)-specific CD4+ T cell response to LAIV strains in children with and without evidence of asymptomatic res-
piratory viral infections at baseline. Antibody response is expressed as the fold-rise in geometric mean titer after vaccination andCD4+ T cell response as the fold-
change after vaccination in the percentage of CD4+ T cells expressing IFN gamma (IFNg) following stimulation with strain-specific HA peptides. The p values are
from Mann-Whitney U test. Shown are median and interquartile range for each plot.







Figure 3. Cell-type-specific gene expression signatures at baseline associated with presence of asymptomatic respiratory viruses and LAIV
shedding in children seronegative to each influenza strain prior to vaccination
(A) Fold-difference in cell-type-specific gene expression scores for different cell types between children with and without asymptomatic respiratory viruses pre-
LAIV challenge. Cell-type-specific expression scores from bulk RNA sequencing (RNA-seq) data were generated using the sum of the normalized expression
values from the top 50 genes defining each cell type derived from a previously described nasal wash single-cell RNA-seq data in influenza-infected individuals.10
Only cell types with a significant difference between groups (Mann-Whitney U test; Figure S1) are displayed. The fold-difference was calculated using the median
values for children positive and negative for asymptomatic respiratory viruses.
(B) GSEA using the Spearman correlation coefficients between rlog prior to LAIV challenge and strain-specific viral loads (log10 EID50/mL) at days 2 and 7 as rank
and cell-type-specific gene set as in Cao et al. (2020).10 The size of circles is proportional to the adjustedlog10 p value fromGSEA, while the intensity of the circle
color denotes the NES for each cell-type/strain-specific viral load combination (deeper color represents higher NES). Blue circles denote enrichment of genes in
nasopharynx prior to LAIV challenge that negatively correlate with viral load at day 2 and day 7, and red circles denote enrichment of genes that positively
correlate with viral loads. Significant pathways (adjusted p value < 0.1) are highlighted with a black outline.
(C) Correlation between cell-type-specific gene expression scores and NESs for the IFN signaling pathway from single sample GSEA using the Reactome
pathway set. Cell-type-specific scores were calculated following exclusion of any genes also present in the IFN signaling pathway gene set to avoid correlation
due to these overlapping genes (classical dendritic cells [DCs]: HLA-DP1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DQB2, HLA-DRB5, IRF8; no overlapping
genes for macrophage, eosinophil, or goblet cell gene sets). R, Spearman correlation coefficient.




macrophages, neutrophils, and eosinophils, as well as a range of
other immune cells, were upregulated in children with asymp-
tomatic viral infections. Significant correlations were seen be-
tween several of these cell-type signatures and interferon
signaling pathways.
Interestingly, we observed upregulation of pathways associ-
ated with ciliary function (Intraflagellar transport, Anchoring of
the basal body to the plasma membrane) at baseline were asso-
ciated with higher LAIV viral loads. In addition, pre-challenge
enrichment for a gene set representative of ciliated epithelial
cells was significantly associated with higher viral loads at later
time points. Asymptomatic viral infection also resulted in reduc-
tion in cell-type expression scores for several epithelial cells, but
notably for ciliated epithelial cells. This could simply represent a
scenario where loss of epithelial cells due to preceding viral
infection results in a reduction in preferential target cells for influ-
enza infection. Children with greater proportions of ciliated
epithelial cells at the time of infection may end up having higher
influenza viral loads. It is also possible that the infiltration of other
cells during viral infection leads to a lower proportion of epithelial
cells within the total cells sampled or that variability in nasopha-
ryngeal swabbing may have contributed to our observed result.
However, previous data from human airway epithelial cells have
shown that human rhinovirus infection downregulates several
genes associated with cilium movement and morphogenesis,20
with several of these found in the Intraflagellar transport pathway
leading edge genes in our analysis (e.g., DYNC2H1, DYNC2LI1,
IFT20, IFT88, IFT122, IFT172, KIF3A, TTC26, WDR35). These
findings warrant further in vitro exploration to understand the
role of ciliary function genes in facilitating influenza replication.
Our findings would benefit from being replicated in other
studies. Little is known about the variability in mucosal gene
expression in children classified as healthy from diverse
geographical, environmental, and socioeconomic settings. The
burden of asymptomatic respiratory viruses in children will vary
seasonally in the same location as well as between countries.
Nevertheless, it is biologically plausible that a similar relationship
will be seen between upregulated interferon pathways and
impaired replication of LAIV strains regardless of where children
reside. Reassuringly, we did not see any negative impact of
asymptomatic viral infection or upregulated interferon gene
expression pre-vaccination on antibody and T cell responses
to LAIV. While we have shown that shedding of LAIV strains at
day 7 is significantly associated with higher HAI and CD4+
T cell responses to LAIV,5 our current data suggest that the
reduced viral replication associated with pre-upregulated inter-
feron in some children is not sufficient to significantly impair
this immunogenicity.
We present proof of concept that LAIV could be used as a
surrogate influenza challenge model in young children to under-
stand host-virus and virus-virus interactions in the upper respi-
ratory tract. Mucosal transcriptomic studies in pediatric influ-
enza infection to date are limited to sampling after acute
presentation, where pre-infection factors cannot be deter-
mined. Our methodology can also be applied to future pediatric
studies to obtain detailed nasopharyngeal host and pathogen
data from minimally invasive sampling. Integrating such
methods into household viral transmission studies with system-
atic sampling over time should be used to expand our experi-
mental findings with LAIV to other respiratory viruses. This
could be particularly relevant in exploring why children appear
to be less susceptible to symptomatic SARS-CoV-2 infection
and determining whether mucosal factors such as upregulated
ISGs prior to exposure impact acquisition, severity of infection
and onward transmission.
Limitations of the study
Themajor limitation of our study is that only transcriptional signa-
tures were assessed rather than protein and cytokine measure-
ment, or cellular characterization via flow cytometry. Challenges
to sampling in young children limit the ability to undertake exten-
sive investigation, but it would be important to validate our find-
ings in future studies. Although we documented asymptomatic
viral infections at baseline by PCR in more than 40% of children,
it is difficult to know when these children were infected as viral
nucleic acid can be detected for prolonged periods after acute
infection. This may in part explain the heterogeneity in interferon
gene upregulation seen in children with asymptomatic respira-
tory viral infections. It is also not known whether the attenuating
mutations in LAIV strains impact their susceptibility to antiviral in-
terferons, which may affect to what degree our findings are
generalizable to wild-type influenza strains. Despite producing
significantly less infectious virus, LAIV strains have been shown
to induce greater antiviral innate responses in vitro than antigen-
matched seasonal influenza viruses, whichmay contribute to the
attenuated phenotype observed.3
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD4 PerCPCy5.5-conjugated antibody Biolegend 317428; RRID:AB_1186122
CD8 FITC-conjugated antibody Biolegend 301050; RRID:AB_2562055
IL-2 PE-conjugated antibody Biolegend 500307; RRID:AB_315094
IFN- g APC-conjugated antibody Biolegend 506510; RRID:AB_315443
Purified mouse anti-human CD49d BD Biosciences 340976; RRID:AB_400198
Purified mouse anti-human CD28 BD Biosciences 340975; RRID:AB_400197
BD Golgiplug (Protein Transport Inhibitor –
Brefeldin A)
BD Biosciences 555029; RRID:AB_2869014
Anti-Rat Ig, negative control compensation
particles set
BD Biosciences 552844; RRID:AB_10055784)
Anti-Mouse Ig, negative control compensation
particles set
BD Biosciences 552843; RRID:AB_10051478
ARCTM Amine reactive compensation bead
kit (for Live/Dead staining)
Molecular Probes A10346
Zombie Violet Fixable Viability Kit Biolegend 423114
Staphylococcal Enterotoxin B Sigma Aldrich S4811
Bacterial and virus strains
Equine Arteritis Virus RIVM, the Netherlands
(in-house)
N/A
A/Michigan/45/2015(H1N1) pdm09-like virus Worldwide Influenza Centre
at the Crick Institute
(London, UK)
N/A
A/HongKong/4801/2014(H3N2)-like virus Worldwide Influenza Centre
at the Crick Institute
(London, UK)
N/A
A/California/7/2009(H1N1)pdm09-like virus Worldwide Influenza Centre
at the Crick Institute
(London, UK)
N/A
B/Brisbane/60/2008-like virus Worldwide Influenza Centre
at the Crick Institute
(London, UK)
N/A
B/Texas/02/2013)-like virus Worldwide Influenza Centre




Specific ferret post-infection antisera as controls In-House N/A
Chemicals, peptides, and recombinant proteins
Phosphate Buffered Saline (PBS) tablets Sigma P4417 100TAB
Sterile distilled water N/A N/A
70% Ethanol Variable Variable
Pen/strep Variable Variable
RPMI Variable Variable
Foetal Bovine Serum (FBS) GIBCO-Life Technologies 10500-064
Sodium Azide Sigma Aldrich S2002-25G
20mM EDTA Sigma Aldrich E7889-100ml
L- Glutamine Variable Variable
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Influenza overlapping peptide pools
(Matrix and Nucleoprotein – MNP,
H1 haemagglutinin – HA1,
H3 haemagglutinin – HA3,
Influenza B Haemagglutinin- HA,
Influenza B Matrix and Nucleoprotein - MNP)
reconstituted in DMSO and stored at 70C
(so final concentration in assay is 2 mg/ml)
Sigma-Aldrich Custom




Ethanol – molecular grade 96 100% Various Various
RNAprotect Cell Reagent QIAGEN 76526
RNase Zap reagent Various Various
PBS (1X), sterile liquid; pH 7.2 ± 0.05
(-CaCl2, -MgCl2)
GIBCO Invitrogen 20012-019
Physiological Saline; Sodium chloride,
Tablet 1/100mL
Sigma Aldrich S6150-50TAB
HPLC graded distilled water VWR 83645.290
Diethyl ether ACS reagent, anhydrous,
R 99.0%, contains BHT as inhibitor
Sigma Aldrich 346136-250ML
TWEEN 80 10% Low-peroxide Sigma Aldrich P8192-10ML
Receptor Destroying Enzyme (RDE) Accurate Chemical YCC340122
Bovine serum albumin (BSA) Sigma A8327
Oseltamivir Carboxylate Roche GS4071 / Ro64-0802
Critical commercial assays
QubitTM RNA HS Assay kit QIAGEN Q32852
SPLIT RNA Extraction Kit Lexogen 008
QuantSeq 30 mRNA-Seq Library Prep Kit Lexogen 015.24





Copan pediatric flocked eSwab
with Amie’s medium
Copan 484CE
Copan Universal Transport Medium
collection kit with nasopharyngeal
flocked swab
Copan 360C
Copan empty tube for E-Swab PFPM913S
Deposited data
Raw and processed bulk RNA-seq data This paper GEO: GSE159884
Analyses and resources: scripts and codes This paper, Github data https://github.com/csbl-br/Mucosal_
transcriptome_LAIV_shedding
Experimental models: Cell lines
0.5% Turkey erythrocytes In-house
(Public Health England)
NA
0.5% Guinea Pig erythrocytes In-house
(Public Health England)
NA
Multiplex viral assay – Reagents and chemicals
Invitrogen Superscript III platinum 1 step
RT PCR kit
ThermoFisher Scientific 12574018
Platinum Taq DNA Polymerase, DNA-free ThermoFisher Scientific 15966005
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Multiplex viral assay – Oligonucleotides
influenza virus A forward primer Eurogentec AAGACAAGACCAATYCTGTCACCTCT
influenza virus A reverse primer Eurogentec TCTACGYTGCAGTCCYCGCT
influenza virus A probe Eurogentec FAM-TYACGCTCACCGTGCCCAGTG-BHQ1
influenza virus B forward primer Eurogentec ATGATCTTACAGTGGAGGATGAAGAA
influenza virus B reverse primer Eurogentec CGAATTGGCTTTGRATGTCCTT
influenza virus B probe Eurogentec CY5-ATGGCCATCGGATCCTCAAYTC
ACTCT-BHQ1
parainfluenza virus 1 forward primer Eurogentec GTGATTTAAACCCGGTAATTTCTCA
parainfluenza virus 1 reverse primer Eurogentec CCTTGTTCCTGCAGCTATTACAGA
parainfluenza virus 1 probe Eurogentec FAM-ACCTATGACATCAACGAC-BHQ2
parainfluenza virus 2 forward primer Eurogentec ATGAAAACCATTTACCTAAGTGATGGA
parainfluenza virus 2 reverse primer Eurogentec CCTCCYGGTATRGCAGTGACTGAAC
parainfluenza virus 2 probe Eurogentec VIC-TCAATCGCAAAAGC-BHQ2
parainfluenza virus 3 forward primer Eurogentec CCAGGGATATAYTAYAAAGGCAAAA
parainfluenza virus 3 reverse primer Eurogentec CCGGGRCACCCAGTTGTG
parainfluenza virus 3 probe Eurogentec FAM-TGGRTGTTCAAGACCTCCATA
YCCGAGAAA-BHQ1
parainfluenza virus 4 forward primer Eurogentec CAGAYAACATCAATCGCCTTACAAA
parainfluenza virus 4 reverse primer Eurogentec TGTACCTATGACTGCCCCAAARA
parainfluenza virus 4 probe Eurogentec CY5-CCMATCACAAGCTCAGAAAT
YCAAAGTCGT-BHQ1
Human coronavirus 229E forward primer Eurogentec CAGTCAAATGGGCTGATGCA
Human coronavirus 229E reverse primer Eurogentec AAAGGGCTATAAAGAGAATAAGGTATTCT
Human coronavirus 229E probe Eurogentec FAM-CCCTGACGACCACGTTGTGGTTCA-BHQ1
Human coronavirus OC43 forward primer Eurogentec CCTTCCTGAGCCTTCAATATAGTAACC
Human coronavirus OC43 reverse primer Eurogentec CGATGAGGCTATTCCGACTAGGT
Human coronavirus OC43 probe Eurogentec FAM-TCCGCCTGGCACGGTACTCCCT-BHQ1
Human coronavirus NL63 forward primer Eurogentec ACGTACTTCTATTATGAAGCATGATATTAA
Human coronavirus NL63 reverse primer Eurogentec AGCAGATCTAATGTTATACTTAAAACTACG
Human coronavirus NL63 probe Eurogentec FAM-ATTGCCAAGGCTCCTAAACGTAC
AGGTGTT-BHQ1
rhinovirus forward primer Eurogentec TGGACAGGGTGTGAAGAGC
rhinovirus reverse primer Eurogentec CAAAGTAGTCGGTCCCATCC
rhinovirus probe Eurogentec HEX-TCCTCCGGCCCCTGAATG-BHQ1
Respiratory syncytial virus A forward primer Eurogentec AGATCAACTTCTGTCATCCAGCAA
Respiratory syncytial virus A reverse primer Eurogentec TTCTGCACATCATAATTAGGAG
Respiratory syncytial virus A probe Eurogentec FAM-CACCATCCAACGGAGCACAGGAGAT-BHQ1
Respiratory syncytial virus B forward primer Eurogentec AAGATGCAAATCATAAATTCACAGGA
Respiratory syncytial virus B reverse primer Eurogentec TGATATCCAGCATCTTTAAGTA
Respiratory syncytial virus B probe Eurogentec CY5-TTTCCCTTCCTAACCTGGACATA-BHQ1
Swine Flu forward primer Eurogentec TGTGCCACTTGTGAACAGATTG
Swine Flu reverse primer Eurogentec CTGATTAGTGGATTGGTGGTAGTAGC
Swine Flu probe Eurogentec HEX-TGATTCACAGCATCGGTCTC
ACAGACAG-BHQ1
EVA (RNA ic) forward primer Eurogentec CTGTCGCTTGTGCTCAATTTAC
EVA (RNA ic) reverse primer Eurogentec AGCGTCCGAAGCATCTC
EVA (RNA ic) probe Eurogentec ROX-TGCAGCTTATGTTCCTTGCA
CTGTGTTC-BHQ1
Adenovirus forward primer Eurogentec GCCACGGTGGGGTTTCTAAACTT
Adenovirus reverse primer Eurogentec GCCCCAGTGGTCTTACATGCACATC
(Continued on next page)






Further information and requests for resources and reagents should be directed to andwill be fulfilled by the lead contact, Thushan de
Silva (t.desilva@sheffield.ac.uk).
Materials availability
This study did not generate any new unique reagents available for distribution.
Data and code availability
Code and data used for performing Spearman correlation between viral load data and gene or pathway expression, related to all
figures, are public available at Github repository (https://github.com/csbl-br/Mucosal_transcriptome_LAIV_shedding). The analysis
Continued
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Adenovirus probe Eurogentec FAM-TGCACCAGACCCGGGCTCAGGT
ACTCCGA-BHQ1
Human Metapneumovirus A forward primer Eurogentec GCYGTYAGCTTCAGTCAATTCAA
Human Metapneumovirus A reverse primer Eurogentec TCCAGCATTGTCTGAAAATTGC
Human Metapneumovirus A probe Eurogentec VIC-CAACATTTAGAAACCTTCT-BHQ1
Human Metapneumovirus B forward primer Eurogentec GCYGTYAGCTTCAGTCAATTCAA (Common with A)
Human Metapneumovirus B reverse primer Eurogentec GTTATCCCTGCATTGTCTGAAAACT




DART Lin and Hsu, 2018 https://github.com/hsinnan75/Dart
Flowjo v10.7.1 BD Biosciences N/A
Cytoscape v3.8.0 Cytoscape https://cytoscape.org/
NetworkAnalyst v3.0 Zhou et al., 20197 https://www.networkanalyst.ca/




Rsubread R package Bioconductor N/A
DESeq2 R package v1.24.0 Love et al., 201422 https://bioconductor.org/packages/release/
bioc/html/DESeq2.html
ComplexHeatmap R package v2.0.0 Bioconductor https://bioconductor.org/packages/release/
bioc/html/ComplexHeatmap.html
Ggplot2 R package 3.3.5 CRAN https://cran.r-project.org/web/packages/
ggplot2/index.html
EnhancedVolcano R package v1.2.0 Bioconductor https://bioconductor.org/packages/release/
bioc/html/EnhancedVolcano.html
BiocParallel R package Bioconductor https://bioconductor.org/packages/release/
bioc/html/BiocParallel.html




BD LSR II Fortessa BD Biosciences UK N/A
QubitTM Flurometer QIAGEN Q33238
Illumina NextSeq 500 Illumina NA
Single-cell Data (Single-cell atlas of the
airway epithelium)
Deprez et al., 20208 https://www.genomique.eu/cellbrowser/HCA/
Pathway gene set data (Reactome) Reactome https://reactome.org/download-data




folder contains numbered R and Bash scripts used for data manipulation in one subfolder: data/raw to be used as script inputs. Pro-
cessed files and plots should be obtained by executing script sequentially (order is indicated by file number) using the provided data
as inputs.
Code and data used for plotting corrplots, heatmap, volcano and scatterplots are provided within numbered R scripts. The plots
were manually edited and assembled using Inkscape to improve presentation (https://inkscape.org/) to form the manuscript figures.
Any additional information required to re-analyze the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Study Design, sampling and LAIV inoculation
Influenza-vaccine naive children aged 24-59 months were recruited and administered one dose of trivalent LAIV as previously
described (median age 35 months, 44% female).5 Inclusion and exclusion criteria for the study were as follows:
Inclusion Criteria
d Healthy male or female child at least 24 months of age and less than 60 months of age at the time of study entry.
d Resident in the study area and with no plans to travel outside the study area during the period of subject participation.
d Informed consent for the study participation obtained from a parent (or guardian only if neither parent is alive or if guardianship
has been legally transferred).
d Willingness and capacity to comply with the study protocol as judged by a member of the clinical trial team.
Exclusion Criteria
d Serious, active, medical condition, including but not limited to:
d chronic disease of any body system
d severe protein-energy malnutrition (weight-for-height Z-score of less than 3)
d known genetic disorders, such as Down syndrome or other cytogenetic disorder
d Active wheezing
d History of documented hypersensitivity to eggs or other components of the vaccine (including gelatin, sorbitol, lactalbumin and
chicken protein), or with life-threatening reactions to previous influenza vaccinations.
d History of documented hypersensitivity to macrolide antibiotics
d History of Guillain-Barré syndrome.
d Receipt of aspirin therapy or aspirin-containing therapy within the two weeks before planned study vaccination.
d Any suspected or confirmed congenital or acquired state of immune deficiency including but not limited to primary immuno-
deficiencies including thymus disorders, HIV/AIDS, hematological or lymphoid malignancies.
d Any current immunosuppressive/immunomodulatory treatment or receipt of any such treatment within the six months preced-
ing trial enrolment (for corticosteroids this is defined as a dose of prednisolone (or equivalent) of greater than 2mg/kg/day for
one week or 1mg/kg/day for one month. The use of topical corticosteroids is not an exclusion criterion.
d The use of inhaled corticosteroids within the last one month.
d Receipt of an influenza vaccine within the past 12 months.
d Has any condition determined by investigator as likely to interfere with evaluation of the vaccine or be a significant potential
health risk to the child or make it unlikely that the child would complete the study?
d Any significant signs or symptoms of an acute illness or infection including:
d an axillary temperature of 38.0C or above or documented fever of 38C or above in the preceding 14 days.
d Any acute respiratory infection within 14 days of enrolment visit.
Only children given the 2017-18 northern hemisphere LAIV formulation were included in the current analysis (administered Feb –
April 2018), as this vaccine included three influenza strains with good replicative ability following replacement of the A/California/07/
2009-like pH1N1 strain from previous years.5 Influenza titers per dose (50% Egg Infectious Doses (EID50)/ml) were 1x10
7.7 for pH1N1
(A/17/New York/15/5364), 1x107.6 for H3N2 (A/17/Hong Kong/2014/8296) and 1x107.3 for the influenza B Victoria-lineage strain
(B/Texas/02/2013).
Nasopharyngeal swabs (NPS) were taken pre-LAIV challenge, and at day 2 (D2) and day 7 (D7), using flocked swabs (Copan
FloQSwabsTM) collected directly into RNAprotect Cell Reagent (QIAGEN). Samples were transported at 2-8C and stored at
70C within 4 hours of collection. Whole blood was collected pre-LAIV, serum separated and stored at 70C prior to further
processing.




Ethical approval and consent
The study was approved by the Gambia Government/MRC Joint Ethics Committee (SCC1502) and the Medicines Control Agency of
The Gambia, and conducted according to ICH-GCP standards. Parents provided written or thumbprinted informed consent for their
children to participate.
METHOD DETAILS
Antibody and T cell responses to LAIV
Haemagglutinin inhibition (HAI) assayswere performed according to standardmethods, using vaccine haemagglutinin (HA) and neur-
aminidase-matched viruses.23 Children with baseline HAI titer < 1:10 were classified as seronegative to a given influenza strain. HAI
geometric mean titers were measured before and after (day 21) LAIV, allowing calculation of a geometric mean fold rise (GMFR)
following vaccination. Haemagglutinin-specific CD4+ T cell responses before and after vaccination were measured using intra-
cellular cytokine staining following stimulation with overlapping peptides representing haemagglutinin proteins of vaccine-matched
pH1N1, H3N2 and influenza B strains as previously described.5 A fold change in the percentage of CD4+ T cells expressing inter-
feron-gamma at day 21 compared to day 0 was estimated to evaluate vaccine responses.
Detection of Respiratory Viruses & quantitative RT-PCR for LAIV strains
Total nucleic acid was extracted from 180mL of RNAprotect using the QIAamp Cador Pathogen mini kit (Indical Bioscience Gmbh,
Germany) as per manufacturer’s instructions. All samples were spiked with Equine Arteritis Virus as an extraction control. A previ-
ously described multiplex reverse-transcriptase polymerase-chain reaction (RT-PCR) was performed to detect influenza A, influenza
B, Respiratory Syncytial Virus (RSV) A, RSV B, human parainfluenza viruses (HPIV) 1 to 4, humanmetapneumovirus, adenovirus, sea-
sonal coronaviruses (CoV; 229E, OC43, NL63) and human rhinovirus.6
Total nucleic acid was extracted from 270mL of RNAprotect as described above. LAIV strain viral loads were quantified as previ-
ously described, with monoplex HA-specific RT-PCRs using a standard curve with known log10 50% EID/ml.5 RT-PCR negative
samples were assigned a log10 50% EID/ml based on the lower limit of detection of each assay (0.219 for pH1N1, 0.319 for
H3N2 and 0.619 for influenza B) for the purpose of analyses described below.
RNA-sequencing of nasopharyngeal samples and data processing
RNA was extracted from 400mL of RNAprotect using the SPLIT RNA Extraction Kit (Lexogen) as per manufacturer’s instructions.
Sampleswith at least 100ng of RNAwere taken forward for QuantSeq 30 messenger RNA sequencing (Lexogen).24QuantSeq libraries
were prepared using theQuantSeq 30 mRNA-Seq Library Prep Kit for Illumina according tomanufacturer’s instructions, with the addi-
tion of uniquemolecular identifiers for exclusion of PCR duplicates. Libraries were sequenced using the Illumina NextSeq 500 to pro-
duce 75bp single-end reads for each sample.
Raw data quality control was performed using FastQC (Bioinformatics). Mapping to the human reference genome (GRCh38/hg38)
was done using DART (Lin and Hsu, 2018). PCR duplicates were removed using umi_tools dedup in Python 3.7.2 and optical dupli-
cates removed using the PicardMarkDuplicates tool (http://broadinstitute.github.io/picard/). Readswere counted at gene level using
the Rsubread R package.25 For genes with multiple isoforms, only the transcript which displayed the highest mean expression be-
tween all samples was selected. Raw and processed data are available in the GEO database (GSE159884). Genes with counts < 30
were excluded (leaving 32932 genes) and the data normalized using rlog and varianceStabilizingTransformation (VST) functions from
DESeq2 Bioconductor package.22
Cell type-specific expression scores from bulk RNA-seq data were generated using the sum of the VST-normalized expression
values from the top 50 genes defining each cell type derived from a previously described nasal wash single-cell RNaseq data in influ-
enza-infected individuals.10 Deconvolution of bulk RNA-seq was also performed using the MuSIC package,9 with single-cell atlas
data from human healthy airway tissue as the reference set.8 The scores for each cell type were then compared between children
with and without asymptomatic respiratory viruses, as a surrogate for determining how these infections may affect the presence
of different cell types in the nasopharyngeal mucosa.
QUANTIFICATION AND STATISTICAL ANALYSIS
Bioinformatic analysis
Analyses were conducted in R software version 3.6. Gene set enrichment analyses (GSEA) were conducted using the fgsea Bio-
conductor package.21 A list of Spearman rank correlation coefficients between LAIV viral loads and rlog normalized expression
for each gene was used as a rank. Enrichment analyses were performed using the Reactome pathway set and, in a separate analysis,
the cell-subset marker set (50 defining genes/subset).10 Single sample GSEA using baseline gene expression scores as rank for each
individual was also conducted for Reactome pathways. Normalized enrichment scores (NES) and adjusted P-values for each
pathway/cell type were extracted, along with leading edge genes in each set. Pathways with an adjusted P-value of < 0.1 were
considered significant, which is more conservative than the adjusted P-value threshold of 0.25 used previously in GSEA.26




DESeq2 Bioconductor was used to detect differentially expressed genes (DEG) between children with and without asymptomatic
viral infections prior to LAIV challenge.22 A false discovery rate correction using the Benjamini-Hochberg method was used as stan-
dard for DEG analyses to generate adjusted P-values for each gene. A log2 fold-change of ± 0.5 and a stringent adjusted P-value of
0.001 were used to select DEG for further consideration.
Networks were constructed with NetworkAnalyst 3.0 using InnateDB protein-protein interaction data and the minimum network
option.7 Networks were edited and visualized using Cytoscape (https://cytoscape.org/).
Statistical analysis
Comparisons of continuous data between groups were performed using the Mann Whitney U test. All correlations were estimated
using Spearman’s rank correlation coefficients. Analyses were conducted in R software version 3.6.
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